<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEFPODOXIME PROXETILÂ - cefpodoxime proxetilÂ granule, for suspensionÂ </strong><br>NorthStar Rx LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_23"></a><a name="section-1"></a><p></p>
<br><p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil and other antibacterial drugs, cefpodoxime proxetil should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.<br><br><span class="Bold">For Oral Use Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_1"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Cefpodoxime proxetil is an orally administered, extended spectrum, semi-synthetic antibiotic of the cephalosporin class. The chemical name is (RS)-1(isopropoxycarbonyloxy) ethyl (+)-(6R,7R)-7-[2-(2-amino-4-thiazolyl)-2-{(Z)methoxyimino}acetamido]-3-methoxymethyl-8-oxo-5-thia-1-azabicyclo [4.2.0]oct-2-ene- 2-carboxylate.</p>
<br><p>Its molecular formula is C<span class="Sub">21</span>H<span class="Sub">27</span>N<span class="Sub">5</span>O<span class="Sub">9</span>S<span class="Sub">2</span> and its structural formula is represented below:<br><br><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5310de78-22c3-4bee-9956-854e767b6bef&amp;name=cefpodoxime-str.jpg"></p>
<br><p>The molecular weight of cefpodoxime proxetil is 557.6.</p>
<br><p>Cefpodoxime proxetil is a prodrug; its active metabolite is cefpodoxime. All doses of cefpodoxime proxetil in this insert are expressed in terms of the active cefpodoxime moiety. The drug is supplied as flavored granules for oral suspension.</p>
<br><p>Each 5 mL of cefpodoxime proxetil for oral suspension USP contains cefpodoxime proxetil USP equivalent to 50 mg or 100 mg of cefpodoxime activity after constitution and the following inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, ferric oxide yellow, hydroxypropyl cellulose, microcrystalline cellulose and carboxymethyl cellulose sodium, colloidal silicon dioxide, citric acid anhydrous, sodium citrate, sodium benzoate, sucrose, and citron &amp; vanille flavorings.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_2"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<br><p class="First"><span class="Bold">Absorption and Excretion:</span><br><br>Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Following oral administration of 100 mg of cefpodoxime proxetil to fasting subjects, approximately 50% of the administered cefpodoxime dose was absorbed systemically. Over the recommended dosing range (100 to 400 mg), approximately 29 to 33% of the administered cefpodoxime dose was excreted unchanged in the urine in 12 hours. There is minimal metabolism of cefpodoxime <span class="Italics">in vivo</span>.<span class="Bold"><br><br>Effects of Food:</span><br><br>When a 200 mg dose of the suspension was taken with food, the extent of absorption (mean AUC) and mean peak plasma concentration in fed subjects were not significantly different from fasted subjects, but the rate of absorption was slower with food (48% increase in T<span class="Sub">max</span>).<br><span class="Bold"><br>Pharmacokinetics of Cefpodoxime Proxetil Suspension:</span><br><br>In adult subjects, a 100 mg dose of oral suspension produced an average peak cefpodoxime concentration of approximately 1.5 mcg/mL (range: 1.1 to 2.1 mcg/mL), which is equivalent to that reported following administration of the 100 mg tablet. Time to peak plasma concentration and area under the plasma concentration-time curve (AUC) for the oral suspension were also equivalent to those produced with film-coated tablets in adults following a 100 mg oral dose.<br><br>The pharmacokinetics of cefpodoxime were investigated in 29 patients aged 1 to 17 years. Each patient received a single, oral, 5 mg/kg dose of cefpodoxime oral suspension. Plasma and urine samples were collected for 12 hours after dosing. The plasma levels reported from this study are as follows:Â Â  </p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>CEFPODOXIME PLASMA LEVELS (mcg/mL) IN FASTED PATIENTS (1 to 17 YEARS OF AGE) AFTER SUSPENSION ADMINISTRATION 
			</span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" rowspan="2">Dose<br>(cefpodoxime equivalents)</th>
<th class="Lrule Rrule Toprule" colspan="7">Time after oral ingestion</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">1hr</th>
<th class="Lrule Rrule Toprule" align="center">2hr</th>
<th class="Lrule Rrule Toprule" align="center">3hr</th>
<th class="Lrule Rrule Toprule" align="center">4hr</th>
<th class="Lrule Rrule Toprule" align="center">6hr</th>
<th class="Lrule Rrule Toprule" align="center">8hr</th>
<th class="Lrule Rrule Toprule" align="center">12hr</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="8">
<span class="Sup">1</span> Dose did not exceed 200 mg.<br>
</td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Lrule Rrule" valign="top">Â 5 mg/kg<span class="Sup">1</span><br>
</td>
<td class="Rrule" align="center" valign="top">1.4<br>
</td>
<td class="Rrule" align="center" valign="top">2.1<br>
</td>
<td class="Rrule" align="center" valign="top">2.1<br>
</td>
<td class="Rrule" align="center" valign="top">1.7<br>
</td>
<td class="Rrule" align="center" valign="top">0.9<br>
</td>
<td class="Rrule" align="center" valign="top">0.4<br>
</td>
<td class="Rrule" align="center" valign="top">0.09<br>
</td>
</tr></tbody>
</table>
<br><p><span class="Bold">Distribution:</span><br><br>Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma.<br><br>Skin <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span>:<br><br>Following multiple-dose administration every 12 hours for 5 days of 200 mg or 400 mg cefpodoxime proxetil, the mean maximum cefpodoxime concentration in skin <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> fluid averaged 1.6 and 2.8 mcg/mL, respectively. Skin <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> fluid cefpodoxime levels at 12 hours after dosing averaged 0.2 and 0.4 mcg/mL for the 200 mg and 400 mg multiple-dose regimens, respectively.<br><br>Tonsil Tissue:<br><br>Following a single, oral 100 mg cefpodoxime proxetil film-coated tablet, the mean maximum cefpodoxime concentration in tonsil tissue averaged 0.24 mcg/g at 4 hours post-dosing and 0.09 mcg/g at 7 hours post-dosing. Equilibrium was achieved between plasma and tonsil tissue within 4 hours of dosing. No detection of cefpodoxime in tonsillar tissue was reported 12 hours after dosing. These results demonstrated that concentrations of cefpodoxime exceeded the MIC<span class="Sub">90Â </span> of <span class="Italics">S. pyogenes </span>for at least 7 hours after dosing of 100 mg of cefpodoxime proxetil.<br><br>Lung Tissue:<br><br>Following a single, oral 200 mg cefpodoxime proxetil film-coated tablet, the mean maximum cefpodoxime concentration in lung tissue averaged 0.63 mcg/g at 3 hours post-dosing, 0.52 mcg/g at 6 hours post-dosing, and 0.19 mcg/g at 12 hours post-dosing. The results of this study indicated that cefpodoxime penetrated into lung tissue and produced sustained drug concentrations for at least 12 hours after dosing at levels that exceeded the MIC<span class="Sub">90 </span>for <span class="Italics">S. pneumoniae and H. influenzae</span>.<br><br>CSF:<br><br>Adequate data on CSF levels of cefpodoxime are not available.<span class="Bold"><br><br>Effects of Decreased Renal Function:<br></span>Â <br>Elimination of cefpodoxime is reduced in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (&lt;50 mL/min creatinine clearance). (See <span class="Bold"><span class="Bold"><a href="#Section_6">PRECAUTIONS</a></span></span> and <span class="Bold"><span class="Bold"><span class="Bold"><span class="Bold"><a href="#Section_10">DOSAGE AND ADMINISTRATION</a></span></span></span></span>.) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours. In subjects with moderate (30 to 49 mL/min creatinine clearance) or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (5 to 29 mL/min creatinine clearance), the half-life increased to 5.9 and 9.8 hours, respectively. Approximately 23% of the administered dose was cleared from the body during a standard 3-hour hemodialysis procedure.<span class="Bold"><br><br>Effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (cirrhosis):</span><br><br>Absorption was somewhat diminished and elimination unchanged in patients with cirrhosis. The mean cefpodoxime T<span class="Sub">1/2 </span>and renal clearance in cirrhotic patients were similar to those derived in studies of healthy subjects. <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span> did not appear to affect values in cirrhotic subjects. No dosage adjustment is recommended in this patient population.<br><br><span class="Bold">Pharmacokinetics in Elderly Subjects:</span><br><br>Elderly subjects do not require dosage adjustments unless they have diminished renal function. (See <span class="Bold"><span class="Bold"><a href="#Section_6">PRECAUTIONS</a></span></span>.) In healthy geriatric subjects, cefpodoxime half-life in plasma averaged 4.2 hours (Vs 3.3 in younger subjects) and urinary recovery averaged 21% after a 400 mg dose was administered every 12 hours. Other pharmacokinetic parameters (C<span class="Sub">max</span>, AUC, and T<span class="Sub">max</span>) were unchanged relative to those observed in healthy young subjects.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology:</h2>
<p class="First"><span class="Underline">Mechanism of Action:<br></span><br>Cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefpodoxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.<br><span class="Underline"><br>Mechanism of Resistance:<br></span><br>Resistance to Cefpodoxime is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability.<br><br>Cefpodoxime has been shown to be active against most isolates of the following bacteria, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the Indications and Usage (1) section:<br><span class="Bold"><br>Gram-positive bacteria:<br></span><span class="Italics"><br>Staphylococcus aureus </span>(methicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>, including those producing penicillinases)<br><span class="Italics">Staphylococcus saprophyticus<br></span><span class="Italics">Streptococcus pneumoniae </span>(excluding penicillin-resistant isolates)<br><span class="Italics">Streptococcus pyogenes </span></p>
<br><p><span class="Bold">Gram-negative bacteria:</span></p>
<br><p><span class="Italics">Escherichia coli<br></span><span class="Italics">Klebsiella pneumoniae<br></span><span class="Italics">Proteus mirabilis<br></span><span class="Italics">Haemophilus influenzae </span>(including beta-lactamase producing isolates)<br><span class="Italics">Moraxella catarrhalis<br></span><span class="Italics">Neisseria gonorrhoeae </span>(including penicillinase-producing isolates)</p>
<br><p>The following <span class="Italics">in vitro </span>data are available, but their clinical significance is unknown. At least 90 percent of the following microorganisms exhibit an <span class="Italics">in vitro </span><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less than or equal to the susceptible breakpoint for Cefpodoxime. However, the efficacy of Cefpodoxime in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms has not been established in adequate and well-controlled clinical trials. </p>
<p><span class="Bold">Gram-positive bacteria: </span><span class="Bold"></span></p>
<p><span class="Italics">Streptococcus agalactiae<br></span><span class="Italics">Streptococcus spp. (Groups C, F, G) </span></p>
<p><span class="Bold">Gram-negative bacteria:</span><span class="Bold"></span></p>
<p><span class="Italics">Citrobacter diversus<br></span><span class="Italics">Klebsiella oxytoca<br></span><span class="Italics">Proteus vulgaris<br></span><span class="Italics">Providencia rettgeri<br></span><span class="Italics">Haemophilus parainfluenzae</span><span class="Bold"></span></p>
<br><p><span class="Bold">Anaerobic Gram-positive bacteria</span>:<span class="Italics"></span></p>
<p><span class="Italics">Peptostreptococcus magnus<br></span><span class="Underline"><br>Susceptibility Test Methods:<br></span><br>When available, the clinical microbiology laboratory should provide the results of <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.<br><span class="Underline"><br>Dilution techniques:<br></span><br>Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method <span class="Sup">1,3</span>. The MIC values should be interpreted according to criteria provided in Table 1.<br><span class="Underline"><br>Diffusion techniques:<br></span><br>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method <span class="Sup">2,3</span>. This procedure uses paper disks impregnated with 10 mcg Cefpodoxime to test the susceptibility of microorganisms to Cefpodoxime. The disk diffusion interpretive criteria are provided in Table 1.</p>
<br><p>Table 1. Susceptibility Test Interpretive Criteria for Cefpodoxime <span class="Sup">2</span>.</p>
<table border="0" cellpadding="0" cellspacing="0" width="99%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" rowspan="2" valign="top">Â <br>Pathogen<br>
</td>
<td class="Rrule" align="center" colspan="3" valign="top"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span> (mcg/mL)<br>
</td>
<td class="Rrule" align="center" colspan="4" valign="top">Disk Diffusion Diameters (mm)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">S<br>
</td>
<td class="Rrule" align="center" valign="top">I<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">R<br>
</td>
<td class="Rrule" align="center" valign="top">S<br>
</td>
<td class="Rrule" align="center" valign="top">I<br>
</td>
<td class="Rrule" align="center" valign="top">R<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Enterobacteriaceae</span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 2<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">â‰¥ 8<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥21<br>
</td>
<td class="Rrule" align="center" valign="top">18 to 20<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 17<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Haemophilus influenzae<span class="Sup">a</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 2<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">-<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥21<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Streptococcus pneumoniae</span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤0.5<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">â‰¥ 2<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Neisseria gonorrhoeae<span class="Sup">a</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤0.5<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">-<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥29<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
<td class="Rrule" align="center" valign="top">-<br>
</td>
</tr>
</tbody></table>
<br><p>Susceptibility of staphylococci to Cefpodoxime may be deduced from testing only penicillin and either cefoxitin or oxacillin.</p>
<p><span class="Sup">a =</span> The current absence of resistant isolates precludes defining any results other than â€œSusceptible.â€? Isolates yielding MIC results other than â€œSusceptibleâ€? should be submitted to a reference laboratory for further testing. </p>
<br><p>A report of <span class="Italics">Susceptible </span>indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentration at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site necessary to inhibit growth of the pathogen. A report of <span class="Italics">Intermediate </span>indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of <span class="Italics">Resistant </span>indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site; other therapy should be selected.</p>
<br><p><span class="Underline">Quality Control:<br></span><br>Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individual performing the test<span class="Sup">1,2,3</span>. Standard Cefpodoxime powder should provide the following range of MIC values noted in Table 2. For the diffusion technique using the 10 mcg disk, the criteria in Table 2 should be achieved.</p>
<br><p>Table 2. <span class="Italics">Acceptable </span>Quality Control Ranges for Cefpodoxime</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span><br>
</td>
<td class="Rrule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span> (mcg/mL)<br>
</td>
<td class="Rrule" align="center" valign="top">Disk Diffusion Zone diameters (mm)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Escherichia coli ATCC </span>25922<br>
</td>
<td class="Rrule" align="center" valign="top">0.25Â  to 1<br>
</td>
<td class="Rrule" align="center" valign="top">23 Â to 28<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Haemophilus influenzae </span>ATCC 49247<br>
</td>
<td class="Rrule" align="center" valign="top">0.25 to 1<br>
</td>
<td class="Rrule" align="center" valign="top">25Â  to 31<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Streptococcus pneumoniae </span>ATCC 49619<br>
</td>
<td class="Rrule" align="center" valign="top">0.03 to 0.12<br>
</td>
<td class="Rrule" align="center" valign="top">28 to 34<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Neisseria gonorrhoeae ATCC </span>49226<br>
</td>
<td class="Rrule" align="center" valign="top">0.03Â  to 0.12<br>
</td>
<td class="Rrule" align="center" valign="top">35Â  to 43<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Staphylococcus aureus ATCC 25923</span><br>
</td>
<td class="Rrule" align="center" valign="top">---------<br>
</td>
<td class="Rrule" align="center" valign="top">19Â  to 25<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Staphylococcus aureus ATCC </span>29213<br>
</td>
<td class="Rrule" align="center" valign="top">1Â  to 8<br>
</td>
<td class="Rrule" align="center" valign="top">--------<br>
</td>
</tr>
</tbody></table>
<br><p>ATCC<span class="Sup">Â®</span> is a registered trademark of the American Type Culture Collection.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_3"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<br><p class="First">Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the conditions listed below.<br><br><span class="Bold">Recommended dosages, durations of therapy, and applicable patient populations vary among these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Please see <a href="#Section_10">DOSAGE AND ADMINISTRATION</a> for specific recommendations. Acute <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span> </span><span class="Bold">media</span> caused by <span class="Italics">Streptococcus pneumoniae</span> (excluding penicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Streptococcus pyogenes</span>, <span class="Italics">Haemophilus influenzae</span> (including beta-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), or <span class="Italics">Moraxella (Branhamella) </span><span class="Italics">catarrhalis</span> (including beta-lactamase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> and/or <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> </span>caused by <span class="Italics">Streptococcus pyogenes</span>.<br><br><span class="Bold">NOTE: </span>Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> are not available.<br><br><span class="Bold">Community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> </span>caused by <span class="Italics">S. pneumoniae</span> or<span class="Italics"> H. Influenzae </span>(including beta-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="257905" conceptname="Mucopurulent chronic bronchitis">Acute bacterial exacerbation of chronic bronchitis</span> </span>caused by <span class="Italics">S. pneumoniae</span>, <span class="Italics">H. influenzae </span>(non-beta-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> only), or <span class="Italics">M. catarrhalis</span>. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> caused by beta-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">H. influenzae</span>.<br><br><span class="Bold">Acute, uncomplicated urethral and cervical <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> </span>caused by <span class="Italics">Neisseria gonorrhoeae</span> (including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).<br><br><span class="Bold">Acute, uncomplicated ano-rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in women </span>due to <span class="Italics">Neisseria gonorrhoeae </span>(including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).<br><br><span class="Bold">NOTE: </span>The efficacy of cefpodoxime in treating male patients with rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">N. gonorrhoeae</span> has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">N. gonorrhoeae</span> in men or women.<br><br><span class="Bold">Uncomplicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </span>caused by <span class="Italics">Staphylococcus aureus</span> (including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>) or <span class="Italics">Streptococcus pyogenes</span>. <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscesses</span> should be surgically drained as clinically indicated.<br><br><span class="Bold">NOTE: </span>In clinical trials, successful treatment of uncomplicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> was dose-related. The effective therapeutic dose for <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span> was higher than those used in other recommended indications. (See <span class="Bold"><span class="Bold"><a href="#Section_10">DOSAGE AND ADMINISTRATION</a></span></span>.)<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="141323" conceptname="Acute maxillary sinusitis">Acute maxillary sinusitis</span> </span>caused by <span class="Italics">Haemophilus influenzae </span>(including beta-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Streptococcus pneumoniae</span>, and <span class="Italics">Moraxella catarrhalis</span>.<br><br><span class="Bold">Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> (<span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>) </span>caused by <span class="Italics">Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis</span>, or <span class="Italics">Staphylococcus saprophyticus</span>.<br><br><span class="Bold">NOTE: </span>In considering the use of cefpodoxime proxetil in the treatment of <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, cefpodoxime proxetilâ€™s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents. (See <span class="Bold"><a href="#Section_13">CLINICAL STUDIES</a></span> section.)<br><br>Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly.<br><br>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil and other antibacterial drugs, cefpodoxime proxetil should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.Â In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.Â </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<br><p class="First">Cefpodoxime proxetil is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to cefpodoxime or to the cephalosporin group of antibiotics.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Section_5"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<br><p class="First"><span class="Bold">BEFORE THERAPY WITH CEFPODOXIME PROXETIL IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEFPODOXIME, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF CEFPODOXIME IS TO BE ADMINISTERED TO PENICILLIN SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">PENICILLIN ALLERGY</span>. IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO CEFPODOXIME PROXETIL OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.</span><br><br><span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including cefpodoxime proxetil, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span><br><br><span class="Italics">C. difficile </span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.<br><br>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.<br><br>A concerted effort to monitor for <span class="Italics">C. difficile </span>in cefpodoxime-treated patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was undertaken because of an increased incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> associated with <span class="Italics">C. difficile</span> in early trials in normal subjects. <span class="Italics">C. difficile</span> organisms or toxin was reported in 10% of the cefpodoxime-treated adult patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; however, no specific diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> was made in these patients.<br><br>In post-marketing experience outside the United States, reports of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> associated with the use of cefpodoxime proxetil have been received.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Section_6"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<br><div class="Section" data-sectionCode="34072-9">
<a name="Section_6.1"></a><a name="section-7.1"></a><p></p>
<h2>General:</h2>
<br><p class="First">In patients with transient or persistent reduction in urinary output due to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, the total daily dose of cefpodoxime proxetil should be reduced because high and prolonged serum antibiotic concentrations can occur in such individuals following usual doses. Cefpodoxime, like other cephalosporins, should be administered with caution to patients receiving concurrent treatment with potent diuretics. (See <span class="Bold"><a href="#Section_10">DOSAGE AND ADMINISTRATION</a></span>.)Â <br><br>As with other antibiotics, prolonged use of cefpodoxime proxetil may result in overgrowth of non-susceptible organisms. Repeated evaluation of the patientâ€™s condition is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken.Â <br><br>Prescribing cefpodoxime proxetil in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_6.2"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients:</h2>
<br><p class="First">Patients should be counseled that antibacterial drugs including cefpodoxime proxetil should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When cefpodoxime proxetil is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefpodoxime proxetil or other antibacterial drugs in the future.<br><br><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_6.4"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions:</h2>
<br><p class="First"><span class="Italics">Antacids:</span> Concomitant administration of high doses of antacids (sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and aluminum hydroxide) or H<span class="Sub">2</span> blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. The rate of absorption is not altered by these concomitant medications. Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in T<span class="Sub">max</span>), but do not affect the extent of absorption (AUC).<span class="Italics"><br><br>Probenecid:</span> As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels.<br><span class="Italics"><br>Nephrotoxic drugs:</span> Although <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> has not been noted when cefpodoxime proxetil was given alone, close monitoring of renal function is advised when cefpodoxime proxetil is administered concomitantly with compounds of known nephrotoxic potential.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="Section_6.5"></a><a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions:</h2>
<br><p class="First">Cephalosporins, including cefpodoxime proxetil, are known to occasionally induce a positive direct Coombsâ€™ test.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_6.6"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<br><p class="First">Long-term animal carcinogenesis studies of cefpodoxime proxetil have not been performed. Mutagenesis studies of cefpodoxime, including the Ames test both with and without metabolic activation, the chromosome aberration test, the unscheduled DNA synthesis assay, mitotic recombination and gene conversion, the forward gene mutation assay and the <span class="Italics">in vivo</span> micronucleus test, were all negative. No untoward effects on fertility or reproduction were noted when 100 mg/kg/day or less (2 times the human dose based on mg/m<span class="Sup">2</span>) was administered orally to rats.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_6.7"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="Section_6.7.1"></a><a name="section-7.6.1"></a><p></p>
<h3>Teratogenic Effects:</h3>
<br><p class="First">Pregnancy Category B<br><br>Cefpodoxime proxetil was neither teratogenic nor embryocidal when administered to rats during organogenesis at doses up to 100 mg/kg/day (2 times the human dose based on mg/m<span class="Sup">2</span>) or to rabbits at doses up to 30 mg/kg/day (1 to 2 times the human dose based on mg/m<span class="Sup">2</span>).Â Â <br><br>There are, however, no adequate and well-controlled studies of cefpodoxime proxetil use in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="Section_6.8"></a><a name="section-7.7"></a><p></p>
<h2>Labor and Delivery:</h2>
<br><p class="First">Cefpodoxime proxetil has not been studied for use during labor and delivery. Treatment should only be given if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_6.9"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers:</h2>
<br><p class="First">Cefpodoxime is excreted in human milk. In a study of 3 lactating women, levels of cefpodoxime in human milk were 0%, 2% and 6% of concomitant serum levels at 4 hours following a 200 mg oral dose of cefpodoxime proxetil. At 6 hours post-dosing, levels were 0%, 9% and 16% of concomitant serum levels. Because of the potential for serious reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_6.10"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use:</h2>
<br><p class="First">Safety and efficacy in infants less than 2 months of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_6.11"></a><a name="section-7.10"></a><p></p>
<h2>Geriatric Use:</h2>
<br><p class="First">Of the 3338 patients in multiple-dose clinical studies of cefpodoxime proxetil film-coated tablets, 521 (16%) were 65 and over, while 214 (6%) were 75 and over. No overall differences in effectiveness or safety were observed between the elderly and younger patients. In healthy geriatric subjects with normal renal function, cefpodoxime half-life in plasma averaged 4.2 hours and urinary recovery averaged 21% after a 400 mg dose was given every 12 hours for 15 days. Other pharmacokinetic parameters were unchanged relative to those observed in healthy younger subjects. <br><br>Dose adjustment in elderly patients with normal renal function is not necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_7"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-8.1"></a><p></p>
<h2>Clinical Trials:</h2>
<br><p class="First">In clinical trials using multiple doses of cefpodoxime proxetil granules for oral suspension, 2128 pediatric patients (93% of whom were less than 12 years of age) were treated with the recommended dosages of cefpodoxime (10 mg/kg/day Q 24 hours or divided Q 12 hours to a maximum equivalent adult dose). There were no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> or permanent disabilities in any of the patients in these studies. Twenty-four patients (1.1%) discontinued medication due to adverse events thought possibly or probably related to study drug. Primarily, these discontinuations were for <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>, usually <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>.<br><br>Adverse events thought possibly or probably related, or of unknown relationship to cefpodoxime proxetil for oral suspension in multiple dose clinical trials (N=2128 patients treated with cefpodoxime) were:<br><span class="Bold"><br><br>Incidence Greater Than 1%:</span><br><br>Â Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  6%<br><br>The incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in infants and toddlers (age 1 month to 2 years) was 12.8%.<br><br>Â Â Â <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">Diaper rash</span>/Fungal <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  2% (includes <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>)<br><br>The incidence of <span class="product-label-link" type="condition" conceptid="200164" conceptname="Diaper rash">diaper rash</span> in infants and toddlers was 8.5%.<br><br>Â Â Â Other <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  1.8%<br>Â Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  2.3%<span class="Bold"><br><br>Incidence Less Than 1%:</span><span class="Italics"><br><br>Body:</span>Localized <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramp</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, monilia, generalized <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>.<span class="Italics"><br><br>Digestive:</span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, monilia, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>.<span class="Italics"><br><br>Hemic &amp; Lymphatic:</span><span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">Thrombocythemia</span>, positive direct Coombsâ€™ test, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, prolonged partial thromboplastin time, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>.<span class="Italics"><br><br>Metabolic &amp; Nutritional: </span>Increased SGPT.<span class="Italics"><br><br>Musculo-Skeletal:</span><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>.<span class="Italics"><br><br>Nervous:</span><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucination</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.<span class="Italics"><br><br>Respiratory:</span><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>.<span class="Italics"><br><br>Skin:</span>Skin <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">fungal dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>.<br><span class="Italics"><br>Special Senses:</span><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-8.2"></a><p></p>
<h2>Laboratory Changes</h2>
<br><p class="First">Significant laboratory changes that have been reported in adult and pediatric patients in clinical trials of cefpodoxime proxetil, without regard to drug relationship, were:<br><br><span class="Italics">Hepatic:</span> Transient increases in AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), ALT (SGPT), GGT, alkaline phosphatase, bilirubin, and LDH.<br><br><span class="Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="4203353" conceptname="Granulocytosis">granulocytosis</span>, <span class="product-label-link" type="condition" conceptid="314617" conceptname="Basophilia">basophilia</span>, <span class="product-label-link" type="condition" conceptid="434910" conceptname="Monocytosis">monocytosis</span>, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span>, <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">decreased hemoglobin</span>, decreased hematocrit, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocythemia</span>, positive Coombsâ€™ test, and prolonged PT, and PTT.<br><br><span class="Italics">Serum Chemistry:</span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span>, <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.<br><br><span class="Italics">Renal:</span>Â Increases in BUN and creatinine.<br><br>Most of these abnormalities were transient and not clinically significant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-8.3"></a><p></p>
<h2>Post-marketing Experience:</h2>
<br><p class="First">The following serious adverse experiences have been reported: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> and <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like reactions, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span> with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectorrhagia</span> with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, acute <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, <span class="Italics">in utero</span> exposure with <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>, purpuric <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, pulmonary infiltrate with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, and eyelid <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>.<br><br>One <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was attributed to <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> and <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.4"></a><a name="section-8.4"></a><p></p>
<h2>Cephalosporin Class Labeling:</h2>
<br><p class="First">In addition to the adverse reactions listed above which have been observed in patients treated with cefpodoxime proxetil, the following adverse reactions and altered laboratory tests have been reported for cephalosporin class antibiotics:<br><br><span class="Italics">Adverse Reactions and Abnormal Laboratory Tests:</span> Renal dysfunction, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, hepatic dysfunction including <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like reaction, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.<br><br>Several cephalosporins have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> when the dosage was not reduced. (See <span class="Bold"><a href="#Section_10">DOSAGE AND ADMINISTRATION</a></span> and <span class="Bold"><span class="Bold"><a href="#Section_9">OVERDOSAGE</a></span></span>.) If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_9"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<br><p class="First">In acute rodent toxicity studies, a single 5 g/kg oral dose produced no adverse effects.Â <br><br>In the event of serious toxic reaction from overdosage, hemodialysis or peritoneal dialysis may aid in the removal of cefpodoxime from the body, particularly if renal function is compromised.Â <br><br>The toxic symptoms following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of beta-lactam antibiotics may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_10"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<br><p class="First"><span class="Bold">(See <a href="#Section_3">INDICATIONS AND USAGE</a> for indicated pathogens.)</span><br><br>Cefpodoxime proxetil for oral suspension may be given without regard to food. The recommended dosages, durations of treatment, and applicable patient populations are as described in the following chart: </p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="595">
<caption><span>Adults and Adolescents (age 12 years and older): 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></th>
<th class="Lrule Rrule Toprule" align="center">Total Daily Dose</th>
<th class="Lrule Rrule Toprule" align="center">Dose Frequency</th>
<th class="Lrule Rrule Toprule" align="center">Duration</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Â <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> and/or <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span><br>
</td>
<td class="Rrule" align="center" valign="top">200 mg<br>
</td>
<td class="Rrule" align="center" valign="top">100 mg Q 12 hours<br>
</td>
<td class="Rrule" align="center" valign="top">5 to 10 days<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Acute community-acquiredÂ <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span><br>
</td>
<td class="Rrule" align="center" valign="top">400 mg<br>
</td>
<td class="Rrule" align="center" valign="top">200 mg Q 12 hours<br>
</td>
<td class="Rrule" align="center" valign="top">14 days<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> (men and women) and rectalÂ gonococcal infectionsÂ (women)<br>
</td>
<td class="Rrule" align="center" valign="top">200 mg<br>
</td>
<td class="Rrule" align="center" valign="top">single dose<br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Skin and skin structure<br>
</td>
<td class="Rrule" align="center" valign="top">800 mg<br>
</td>
<td class="Rrule" align="center" valign="top">400 mg Q 12 hours<br>
</td>
<td class="Rrule" align="center" valign="top">7 to 14 days<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â <span class="product-label-link" type="condition" conceptid="141323" conceptname="Acute maxillary sinusitis">Acute maxillary sinusitis</span><br>
</td>
<td class="Rrule" align="center" valign="top">400 mg<br>
</td>
<td class="Rrule" align="center" valign="top">200 mg Q 12 hours<br>
</td>
<td class="Rrule" align="center" valign="top">10 days<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â Uncomplicated urinary tract Â <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span><br>
</td>
<td class="Rrule" align="center" valign="top">200 mg<br>
</td>
<td class="Rrule" align="center" valign="top">100 mg Q 12 hours<br>
</td>
<td class="Rrule" align="center" valign="top">7 days<br>
</td>
</tr>
</tbody>
</table>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Infants and Pediatric Patients (age 2 months through 12 years) 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></th>
<th class="Lrule Rrule Toprule" align="center">Total Daily Dose</th>
<th class="Lrule Rrule Toprule" align="center">Dose Frequency</th>
<th class="Lrule Rrule Toprule" align="center">Duration</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Â Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span><br>
</td>
<td class="Rrule" align="center" valign="top">10 mg/kg/day<br>(Max 400 mg/day)<br>
</td>
<td class="Rrule" align="center" valign="top">5 mg/kg Q 12 h<br>(Max 200 mg/dose)<br>
</td>
<td class="Rrule" align="center" valign="top">5 days<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> and/or <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span><br>
</td>
<td class="Rrule" align="center" valign="top">10 mg/kg/day<br>(Max 200 mg/day)<br>
</td>
<td class="Rrule" align="center" valign="top">5 mg/kg/dose Q 12 h<br>(Max 100 mg/dose)<br>
</td>
<td class="Rrule" align="center" valign="top">5 to 10 days<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â <span class="product-label-link" type="condition" conceptid="141323" conceptname="Acute maxillary sinusitis">Acute maxillary sinusitis</span><br>
</td>
<td class="Rrule" align="center" valign="top">10 mg/kg/day<br>(Max 400 mg/day)<br>
</td>
<td class="Rrule" align="center" valign="top">5 mg/kg Q 12 hours<br>(Max 200 mg/dose)<br>
</td>
<td class="Rrule" align="center" valign="top">10 days<br>
</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_10.1"></a><a name="section-10.1"></a><p></p>
<h2>Patients with Renal Dysfunction:</h2>
<br><p class="First">For patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (&lt;30 mL/min creatinine clearance), the dosing intervals should be increased to Q 24 hours. In patients maintained on hemodialysis, the dose frequency should be 3 times/week after hemodialysis.<br><br>When only the serum creatinine level is available, the following formula (based on sex, weight, and age of the patient) may be used to estimate creatinine clearance (mL/min). For this estimate to be valid, the serum creatinine level should represent a steady state of renal function.<br><br>Â Â Â Males:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  <span class="Underline">Weight (kg) x (140 - age)</span><br>Â Â Â (mL/min) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  72 x serum creatinine (mg/100 mL)<br><br>Â Â Â Females: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  0.85 x above value<br>Â Â Â (mL/min)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_10.2"></a><a name="section-10.2"></a><p></p>
<h2>Patients with Cirrhosis:</h2>
<br><p class="First">Cefpodoxime pharmacokinetics in cirrhotic patients (with or without <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>) are similar to those in healthy subjects. Dose adjustment is not necessary in this population.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_10.3"></a><a name="section-10.3"></a><p></p>
<h2>Directions for use:</h2>
<br><p class="First">Before reconstitution, remove the desiccant capsule by pulling out two small rings, then throw it.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_10.4"></a><a name="section-10.4"></a><p></p>
<h2>Preparation of Suspension:</h2>
<table border="0" cellpadding="0" cellspacing="0" width="border-collapse: collapse"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="3" valign="top">
<span class="Bold">Constitution Directions For Oral Suspension </span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Constituted Volume<span class="Bold"></span><br>
</td>
<td class="Rrule" valign="top">Final <br>Concentration<span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">Directions<span class="Bold"></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">50 mL<br>
</td>
<td class="Rrule" valign="top">50 mg per 5 mL<br>
</td>
<td class="Rrule" valign="top">Suspend in a total of 31 mL of distilled water. Method:<br>First, shake the bottle to loosen granules. Then add the water in two approximately equal portions, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> vigorously after each aliquot of water.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">75 mL<br>
</td>
<td class="Rrule" valign="top">50 mg per 5 mL<br>
</td>
<td class="Rrule" valign="top">Suspend in a total of 44 mL of distilled water. Method:<br>First, shake the bottle to loosen granules. Then add the water in two approximately equal portions, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> vigorously after each aliquot of water.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">100 mL<br>
</td>
<td class="Rrule" valign="top">50 mg per 5 mL<br>
</td>
<td class="Rrule" valign="top">Suspend in a total of 57 mL of distilled water. Method:<br>First, shake the bottle to loosen granules. Then add the water in two approximately equal portions, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> vigorously after each aliquot of water.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">50 mL<br>
</td>
<td class="Rrule" valign="top">100 mg per 5 mL<br>
</td>
<td class="Rrule" valign="top">Suspend in a total of 30 mL of distilled water. Method:<br>First, shake the bottle to loosen granules. Then add the water in two approximately equal portions, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> vigorously after each aliquot of water.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">75 mL<br>
</td>
<td class="Rrule" valign="top">100 mg per 5 mL<br>
</td>
<td class="Rrule" valign="top">Suspend in a total of 43 mL of distilled water. Method:<br>First, shake the bottle to loosen granules. Then add the water in two approximately equal portions, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> vigorously after each aliquot of water.<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">100 mL<br>
</td>
<td class="Rrule" valign="top">100 mg per 5 mL<br>
</td>
<td class="Rrule" valign="top">Suspend in a total of 57 mL of distilled water. Method:<br>First, shake the bottle to loosen granules. Then add the water in two approximately equal portions, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> vigorously after each aliquot of water.<br>Â <br>
</td>
</tr>
</tbody></table>
<br><p class="First">After mixing, the suspension should be stored in a refrigerator, 2Â° to 8Â°C (36Â° to 46Â°F). Shake well before using. Keep container tightly closed. The mixture may be used for 14 days. Discard unused portion after 14 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_11"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<br><p class="First"><span class="Bold">Cefpodoxime Proxetil for Oral Suspension, USP </span>provides the equivalent of 50 mg or 100 mg cefpodoxime per 5 mL suspension (when constituted as directed) and is available as off-white colored granular powder in the following sizes:<br><span class="Bold"><br>50 mg/5 mL</span><br><br>Â Â Â Â Â Â Â Â Â  Â 50-mL suspensionÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  NDC 16714-402-01<br>Â Â Â Â Â Â Â Â Â 100-mL suspensionÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â NDC 16714-402-02Â Â Â Â Â Â Â Â Â Â <br><br><span class="Bold">100 mg/5 mL</span><br><br>Â Â Â Â Â Â Â Â Â  Â 50-mL suspensionÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  NDC 16714-403-01<br>Â Â Â Â Â Â Â Â Â 100-mL suspensionÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â NDC 16714-403-02<br><br><span class="Bold">Store </span>unsuspended granules at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room Temperature].<br><br>Directions for mixing are included on the label. After mixing, suspension should be stored in a refrigerator, 2Â° to 8Â°C (36Â° to 46Â°F). Shake well before using. Keep container tightly closed. The mixture may be used for 14 days. Discard unused portion after 14 days.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="Section_14"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<br><ol class="Arabic">
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Ninth Edition</span>. CLSI document M07-A9, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.</li>
<li>Clinical and Laboratory Standards Institute (CLSI).<span class="Italics"> Performance Standards for Antimicrobial Susceptibility Testing; Twenty-third Informational Supplement</span>, CLSI document M100-S23. CLSI document M100-S23, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2013.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard - Eleventh Edition</span> CLSI document M02-A11, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_13"></a><a name="section-13"></a><p></p>
<h1>CLINICAL TRIALS</h1>
<br><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span></span>Â <br><br>In two double-blind, 2:1 randomized, comparative trials performed in adults in the United States, cefpodoxime proxetil was compared to other beta-lactam antibiotics. In these studies, the following bacterial eradication rates were obtained at 5 to 9 days after therapy:</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule">Pathogen</th>
<th class="Lrule Rrule Toprule" align="center">Cefpodoxime</th>
<th class="Lrule Rrule Toprule" align="center">Comparator</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Â E. coli</span><br>
</td>
<td class="Rrule" align="center" valign="top">200/243 (82%)<br>
</td>
<td class="Rrule" align="center" valign="top">99/123 (80%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â Other pathogens<br>
</td>
<td class="Rrule" align="center" valign="top">34/42 (81%)<br>
</td>
<td class="Rrule" align="center" valign="top">23/28 (82%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Â K. pneumoniae</span><br><span class="Italics">Â P. mirabilis</span><br><span class="Italics">Â S. saprophyticus</span><br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
<td class="Rrule" align="center" valign="top">Â  <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â TOTAL<span class="Italics"></span><br>
</td>
<td class="Rrule" align="center" valign="top">234/285 (82%)<br>
</td>
<td class="Rrule" align="center" valign="top">122/151 (81%)<br>
</td>
</tr>
</tbody>
</table>
<p>In these studies, clinical cure rates and bacterial eradication rates for cefpodoxime proxetil were comparable to the comparator agents; however, the clinical cure rates and bacteriologic eradication rates were lower than those observed with some other classes of approved agents for <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>.<br><br><span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> Studies</span><br><br>In controlled studies of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> performed in the United States, where significant rates of beta-lactamase-producing organisms were found, cefpodoxime proxetil was compared to cefixime. In these studies, using very strict evaluability criteria and microbiologic and clinical response criteria at the 4 to 21 day post-therapy follow-up, the following presumptive bacterial eradication/clinical success outcomes (cured and improved) were obtained.</p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule"></th>
<th class="Lrule Rrule Toprule" align="center">Cefpodoxime Proxetil</th>
<th class="Lrule Rrule Toprule" align="center">Cefixime</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Â Pathogen</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">5 mg/kg Q 12 h x 5 d</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Â  </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Â S. pneumoniae </span><br>
</td>
<td class="Rrule" align="center" valign="top">88/122 (72%)<br>
</td>
<td class="Rrule" align="center" valign="top">72/124 (58%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Â H. influenzae</span><br>
</td>
<td class="Rrule" align="center" valign="top">50/76 (66%)<br>
</td>
<td class="Rrule" align="center" valign="top">61/81 (75%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Â M. catarrhalis</span><br>
</td>
<td class="Rrule" align="center" valign="top">22/39 (56%)<br>
</td>
<td class="Rrule" align="center" valign="top">23/41 (56%)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Â S. pyogenes </span><br>
</td>
<td class="Rrule" align="center" valign="top">20/25 (80%)<br>
</td>
<td class="Rrule" align="center" valign="top">13/23 (57%)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â Clinical success rate<span class="Italics"></span><br>
</td>
<td class="Rrule" align="center" valign="top">171/254 (67%)<br>
</td>
<td class="Rrule" align="center" valign="top">165/258 (64%)<br>
</td>
</tr>
</tbody>
</table>
<p><br>Manufactured for: Northstar Rx LLC<br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Memphis, TN 38141<br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Toll Free: 1-800-206-7821<br><br>Manufactured by: Aurobindo Pharma Limited<br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Chitkul (V) - 502 307, A.P., India <br><br>M.L.No.: 78/MD/AP/96/F/B/R<br><br>Revised: 08/2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_17"></a><a name="section-14"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg/5 mL (50 mL Bottle)</h1>
<br><p class="First"><span class="Bold">R<span class="Sub">x</span> only<br>NDC 16714-402-01</span><span class="Bold"><span class="Bold"><br>Cefpodoxime Proxetil<br>for Oral Suspension, USP</span></span><span class="Bold"><br>50Â mg/5 mL*</span><span class="Bold"><span class="Bold"><br>50Â mL when constituted<br></span>Northstar Rx LLC</span></p>
<br><br><div class="Figure"><img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg/5 mL (50 mL Bottle)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5310de78-22c3-4bee-9956-854e767b6bef&amp;name=cefpodoxime-fig1.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_18"></a><a name="section-15"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg/5 mL Carton Label</h1>
<br><p class="First"><span class="Bold">R<span class="Sub">x</span> only<br>NDC 16714-402-01<br></span><span class="Bold"><span class="Bold">Cefpodoxime Proxetil<br>for Oral Suspension, USP</span></span><span class="Bold"><br>50Â mg/5 mL*Â </span><span class="Bold"><span class="Bold"><br>50Â mL when constituted<br></span>Northstar Rx LLC</span><span class="Bold"><span class="Bold"></span><br>Â <img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg/5 mL Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5310de78-22c3-4bee-9956-854e767b6bef&amp;name=cefpodoxime-fig2.jpg"></span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_19"></a><a name="section-16"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 100 mg/5 mL (50 mL Bottle)</h1>
<br><p class="First"><span class="Bold">R<span class="Sub">x</span> only<br>NDC 16714-403-01<br></span><span class="Bold"><span class="Bold">Cefpodoxime Proxetil<br>for Oral Suspension, USP<br></span></span><span class="Bold">100Â mg/5 mL*<br></span><span class="Bold"><span class="Bold">50Â mL when constituted<br></span>Northstar Rx LLC<br><br><img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 100 mg/5 mL (50 mL Bottle)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5310de78-22c3-4bee-9956-854e767b6bef&amp;name=cefpodoxime-fig3.jpg"></span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_20"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 100 mg/5 mL Carton Label</h1>
<br><p class="First"><span class="Bold">R<span class="Sub">x</span> only<br>NDC 16714-403-01</span><br><span class="Bold"><span class="Bold">Cefpodoxime Proxetil<br>for Oral Suspension, USP</span><br></span><span class="Bold">100Â mg/5 mL*Â </span><br><span class="Bold"><span class="Bold">50Â mL when constituted</span><br>Northstar Rx LLC</span></p>
<br><div class="Figure"><img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 100 mg/5 mL Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5310de78-22c3-4bee-9956-854e767b6bef&amp;name=cefpodoxime-fig4.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFPODOXIME PROXETILÂ 		
					</strong><br><span class="contentTableReg">cefpodoxime proxetil granule, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16714-402</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFPODOXIME PROXETIL</strong> (CEFPODOXIME) </td>
<td class="formItem">CEFPODOXIME</td>
<td class="formItem">50Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">Â Â Â Â </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">LEMON (Citron) ,Â VANILLA (Vanille) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16714-402-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16714-402-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065409</td>
<td class="formItem">06/08/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFPODOXIME PROXETILÂ 		
					</strong><br><span class="contentTableReg">cefpodoxime proxetil granule, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16714-403</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFPODOXIME PROXETIL</strong> (CEFPODOXIME) </td>
<td class="formItem">CEFPODOXIME</td>
<td class="formItem">100Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">Â Â Â Â </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">LEMON (Citron) ,Â VANILLA (Vanille) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16714-403-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16714-403-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065409</td>
<td class="formItem">06/08/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>NorthStar Rx LLC
							(830546433)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Aurobindo Pharma Limited (650082092)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aurobindo Pharma Limited</td>
<td class="formItem"></td>
<td class="formItem">918917639</td>
<td class="formItem">ANALYSIS(16714-402, 16714-403), MANUFACTURE(16714-402, 16714-403)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aurobindo Pharma Limited</td>
<td class="formItem"></td>
<td class="formItem">918917647</td>
<td class="formItem">API MANUFACTURE(16714-402, 16714-403)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>504422f8-3d4f-4063-9b48-c9e6e85422bc</div>
<div>Set id: 5310de78-22c3-4bee-9956-854e767b6bef</div>
<div>Version: 2</div>
<div>Effective Time: 20131203</div>
</div>
</div>Â <div class="DistributorName">NorthStar Rx LLC</div></p>
</body></html>
